RT Journal Article
SR Electronic
T1 Genotype-phenotype correlations in <em>SCN8A</em>-related disorders reveal prognostic and therapeutic implications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.22.21253711
DO 10.1101/2021.03.22.21253711
A1 Katrine M Johannesen
A1 Yuanyuan Liu
A1 Cathrine E Gjerulfsen
A1 Mahmoud Koko
A1 Lukas Sonnenberg
A1 Julian Schubert
A1 Christina D Fenger
A1 Ahmed Eltokhi
A1 Maert Rannap
A1 Nils A. Koch
A1 Stephan Lauxmann
A1 Johanna Krüger
A1 Josua Kegele
A1 Laura Canafoglia
A1 Silvana Franceschetti
A1 Thomas Mayer
A1 Johannes Rebstock
A1 Pia Zacher
A1 Susanne Ruf
A1 Michael Alber
A1 Katalin Sterbova
A1 Petra Lassuthová
A1 Marketa Vlckova
A1 Johannes R Lemke
A1 Ilona Krey
A1 Constanze Heine
A1 Dagmar Wieczorek
A1 Judith Kroell-Seger
A1 Caroline Lund
A1 Karl Martin Klein
A1 PY Billie Au
A1 Jong M Rho
A1 Alice W Ho
A1 Silvia Masnada
A1 Pierangelo Veggiotti
A1 Lucio Giordano
A1 Patrizia Accorsi
A1 Christina E Hoei-Hansen
A1 Pasquale Striano
A1 Federico Zara
A1 Helene Verhelst
A1 Judith S.Verhoeven
A1 Bert van der Zwaag
A1 Aster V. E. Harder
A1 Eva Brilstra
A1 Manuela Pendziwiat
A1 Sebastian Lebon
A1 Maria Vaccarezza
A1 Ngoc Minh Le
A1 Jakob Christensen
A1 Mette U Schmidt-Petersen
A1 Sabine Grønborg
A1 Stephen W Scherer
A1 Jennifer Howe
A1 Walid Fazeli
A1 Katherine B Howell
A1 Richard Leventer
A1 Chloe Stutterd
A1 Sonja Walsh
A1 Marion Gerard
A1 Bénédicte Gerard
A1 Sara Matricardi
A1 Claudia M Bonardi
A1 Stefano Sartori
A1 Andrea Berger
A1 Dorota Hoffman-Zacharska
A1 Massimo Mastrangelo
A1 Francesca Darra
A1 Arve Vøllo
A1 M Mahdi Motazacker
A1 Phillis Lakeman
A1 Mathilde Nizon
A1 Cornelia Betzler
A1 Cecilia Altuzarra
A1 Roseline Caume
A1 Agathe Roubertie
A1 Philippe Gélisse
A1 Carla Marini
A1 Renzo Guerrini
A1 Frederic Bilan
A1 Daniel Tibussek
A1 Margarete Koch-Hogrebe
A1 M Scott Perry
A1 Shoji Ichikawa
A1 Elena Dadali
A1 Artem Sharkov
A1 Irina Mishina
A1 Mikhail Abramov
A1 Ilya Kanivets
A1 Sergey Korostelev
A1 Sergey Kutsev
A1 Karen E Wain
A1 Nancy Eisenhauer
A1 Monisa Wagner
A1 Juliann M Savatt
A1 Karen Müller-Schlüter
A1 Haim Bassan
A1 Artem Borovikov
A1 Marie-Cecile Nassogne
A1 Anne Destrée
A1 An-Sofie Schoonjans
A1 Marije Meuwissen
A1 Marga Buzatu
A1 Anna Jansen
A1 Emmanuel Scalais
A1 Siddharth Srivastava
A1 Wen-Hann Tan
A1 Heather E Olson
A1 Tobias Loddenkemper
A1 Annapurna Poduri
A1 Katherine L Helbig
A1 Ingo Helbig
A1 Mark P Fitzgerald
A1 Ethan M Goldberg
A1 Timo Roser
A1 Ingo Borggraefe
A1 Tobias Brünger
A1 Patrick May
A1 Dennis Lal
A1 Damien Lederer
A1 Guido Rubboli
A1 Gaetan Lesca
A1 Ulrike BS Hedrich
A1 Jan Benda
A1 Elena Gardella
A1 Holger Lerche
A1 Rikke S Møller
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.22.21253711.abstract
AB We report detailed functional analyses and genotype-phenotype correlations in 433 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel NaV1.6. Five different clinical subgroups could be identified: 1) Benign familial infantile epilepsy (BFIE) (n=17, normal cognition, treatable seizures), 2) intermediate epilepsy (n=36, mild ID, partially pharmacoresponsive), 3) developmental and epileptic encephalopathy (DEE, n=191, severe ID, majority pharmacoresistant), 4) generalized epilepsy (n=21, mild to moderate ID, frequently with absence seizures), and 5) affected individuals without epilepsy (n=25, mild to moderate ID). Groups 1-3 presented with early-onset (median: four months) focal or multifocal seizures and epileptic discharges, whereas the onset of seizures in group 4 was later (median: 39 months) with generalized epileptic discharges. The epilepsy was not classifiable in 143 individuals. We performed functional studies expressing missense variants in ND7/23 neuroblastoma cells and primary neuronal cultures using recombinant tetrodotoxin insensitive human NaV1.6 channels and whole-cell patch clamping. Two variants causing DEE showed a strong gain-of-function (GOF, hyperpolarising shift of steady-state activation, strongly increased neuronal firing rate), and one variant causing BFIE or intermediate epilepsy showed a mild GOF (defective fast inactivation, less increased firing). In contrast, all three variants causing generalized epilepsy induced a loss-of-function (LOF, reduced current amplitudes, depolarising shift of steady-state activation, reduced neuronal firing). Including previous studies, functional effects were known for 165 individuals. All 133 individuals carrying GOF variants had either focal (76, groups 1-3), or unclassifiable epilepsy (37), whereas 32 with LOF variants had either generalized (14), no (11) or unclassifiable (5) epilepsy; only two had DEE. Computational modeling in the GOF group revealed a significant correlation between the severity of the electrophysiological and clinical phenotypes. GOF variant carriers responded significantly better to sodium channel blockers (SCBs) than to other anti-seizure medications, and the same applied for all individuals of groups 1-3.In conclusion, our data reveal clear genotype-phenotype correlations between age at seizure onset, type of epilepsy and gain- or loss-of-function effects of SCN8A variants. Generalized epilepsy with absence seizures is the main epilepsy phenotype of LOF variant carriers and the extent of the electrophysiological dysfunction of the GOF variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Our pharmacological data indicate that SCBs present a therapeutic treatment option in early onset SCN8A-related focal epilepsy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German research foundation and the Fonds Nationale de la Recherche in Luxembourg (Research Unit FOR-2715, DFG grants Le1030/15-1 and /16-1 to HL, He8155/1-1 to UBSH, He5415/7-1 to IH, FNR grant INTER/DFG/17/11583046 to PM), the German Federal Ministry for Education and Research (BMBF, Treat-ION, 01GM1907A to HL, DL and PM), the foundation no epilep (to HL to partially support LS), the Medical Faculty of the University of Tuebingen (the Fortuene program 2430-00 to SL). KS, PL, MV were funded by grant: MH CR AZV NU20-04-00279. Epi25 was supported by the National Human Genome Research Institute (NHGRI) grants UM1 HG008895 and 5U01HG009088-02, and the Stanley Center for Psychiatric Research at the Broad Institute. SI was employed by and received a salary from Ambry Genetics. SS hold the GlaxoSmithKline Endowed Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. P.S. has received speaker fees and participated at advisory boards for Biomarin, Zogenyx, GW Pharmaceuticals, and has received research funding by ENECTA BV, GW Pharmaceuticals, Kolfarma Srl., Eisai. EM was funded by grant: NIH NINDS K08 NS097633 and Foerderer Award for Excellence from The Childrens Hospital of Philadelphia Research Institute. PV received a speaker fee from Nutricia GmbH, Dr. Schar AG / SPA, Eisai. Nestle, Pediatrica. FZ and PS developed this work within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016). IH was also supported by The Hartwell Foundation through an Individual Biomedical Research Award. This work was also supported by the National Institute for Neurological Disorders and Stroke (K02 NS112600), including support through the Center Without Walls on ion channel function in epilepsy (Channelopathy-associated Research Center, U54 NS108874), the Eunice Kennedy Shriver National Institute of Child Health and Human Development through the Intellectual and Developmental Disabilities Research Center (IDDRC) at Childrens Hospital of Philadelphia and the University of Pennsylvania (U54 HD086984), and by intramural funds of the Childrens Hospital of Philadelphia through the Epilepsy NeuroGenetics Initiative (ENGIN). Research reported in this publication was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001878. This project was also supported in part by the Institute for Translational Medicine and Therapeutics (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics at the Perelman School of Medicine of the University of Pennsylvania.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethical committees or followed other local guidelines as following: The ethics committee of Region Sjælland, Denmark: SJ-91 Ethics Committee Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium Ethical Committees of the Medical Faculty of the University of Munich Ethics Committee at the Research Centre for Medical Genetics, Moscow, Russian Republic Ethics committee of the University of Leipzig (ethical approval 224/16-ek, 402/16-ek)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request